TTL — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Andalusol (SCHEMBL3669300)	0.52	13/20
SCHEMBL8733662	0.51	11/20
SCHEMBL8733664	0.51	11/20
SCHEMBL10879525	0.39	7/20
SCHEMBL25666849	0.39	7/20
SCHEMBL25666942	0.35	6/20
Scopadiol (SCHEMBL16610408)	0.44	5/20
Scoparic Acid A (SCHEMBL16610421)	0.38	5/20
Scoparic Acid A (SCHEMBL30621453)	0.38	5/20
Scoparic Acid A (SCHEMBL31051329)	0.38	5/20
SCHEMBL3970172	0.37	5/20
SCHEMBL4780814	0.37	5/20
SCHEMBL4781025	0.37	5/20
SCHEMBL5861696	0.37	5/20
SCHEMBL12260912	0.37	5/20
SCHEMBL15514413	0.37	5/20
SCHEMBL21617318	0.37	5/20
SCHEMBL29542590	0.37	5/20
SCHEMBL25666790	0.36	5/20
SCHEMBL14275248	0.31	5/20

Clinical trials — most relevant to TTL by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer	PHASE3	COMPLETED
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)	PHASE3	RECRUITING
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Vit D and Peripheral Neuropathy in Taxane Naive Patients	PHASE2	UNKNOWN
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients	PHASE2	RECRUITING
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel	PHASE1	COMPLETED
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma	PHASE1	COMPLETED
Importance of the Microtubule Cytoskeleton in Oocyte Competence	nan	COMPLETED
The Impact of Mitochondrial Dysfunction on Human Bone Cell Metabolism and Remodelling	nan	ACTIVE_NOT_RECRUITING
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia	nan	UNKNOWN
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Myotubular Myopathy Genetic Testing Study	nan	COMPLETED
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC	nan	UNKNOWN
Diagnostic of Chemotherapy Induced Neuropathy in Children	nan	COMPLETED
Epithelial Mesenchymal Transition and Periodontitis	nan	UNKNOWN
Understanding Evidence-Based Practice Patterns in Advanced NSCLC	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Genetics of Familial Testicular Cancer	nan	COMPLETED
Nasal Brushing for the Diagnosis and Understanding of Telomeropathies	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TTL binder may also engage these)

Protein	Name	Similarity
P38584	—	1.000	P38584 →
Q9QXJ0	—	1.000	Q9QXJ0 →
P38160	—	0.999	P38160 →
P38585	—	0.998	P38585 →
O95922	—	0.978	O95922 →
Q0VC71	—	0.977	Q0VC71 →
Q5PPI9	—	0.970	Q5PPI9 →
Q91V51	—	0.969	Q91V51 →
Q3SZH6	—	0.968	Q3SZH6 →
P0AES0	—	0.963	P0AES0 →
Q641W7	—	0.963	Q641W7 →
Q10438	—	0.963	Q10438 →
Q3UDE2	—	0.963	Q3UDE2 →
O02697	—	0.962	O02697 →
P0AES1	—	0.962	P0AES1 →
A2APC3	—	0.962	A2APC3 →
PIK3CG	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	0.961	landscape →
RAPGEF4	Rap guanine nucleotide exchange factor 4	0.960	landscape →
Q9QXM0	—	0.960	Q9QXM0 →
Q8BTI9	—	0.960	Q8BTI9 →
Q8C0L9	—	0.959	Q8C0L9 →
E1BMP7	—	0.959	E1BMP7 →
A2RV18	—	0.959	A2RV18 →
Q9VUV9	—	0.959	Q9VUV9 →
Q80VJ4	—	0.959	Q80VJ4 →
Q9QUL6	—	0.959	Q9QUL6 →
A6N6J5	—	0.959	A6N6J5 →
Q8N1G2	—	0.958	Q8N1G2 →
Q05AK6	—	0.958	Q05AK6 →
Q92503	—	0.958	Q92503 →